Mechanisms and Therapeutic Potential of Myofibroblast Transformation in Pulmonary Fibrosis
Journal of Respiratory Biology and Translational Medicine · 2025 · 2 (1) · 10001-10001
DOI: 10.70322/jrbtm.2025.10001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Respiratory Biology and Translational Medicine, 2025. Verfasst von Tianming Zhao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology & Toxicology, Medical College of Georgia at Augusta University, Augusta, GA 30912, USA. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 245 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: BLRD VA, NHLBI NIH HHS.
Abstract (Originalsprache)
Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible, and fatal disease with an increasing incidence and limited therapeutic options. It is characterized by the formation and deposition of excess extracellular matrix proteins resulting in the gradual replacement of normal lung architecture by fibrous tissue. The cellular and molecular mechanism of IPF has not been fully understood. A hallmark in IPF is pulmonary fibroblast to myofibroblast transformation (FMT). During excessive lung repair upon exposure to harmful stimuli, lung fibroblasts transform into myofibroblasts under stimulation of cytokines, chemokines, and vesicles from various cells. These mediators interact with lung fibroblasts, initiating multiple signaling cascades, such as TGFβ1, MAPK, Wnt/β-catenin, NF-κB, AMPK, endoplasmic reticulum stress, and autophagy, contributing to lung FMT. Furthermore, single-cell transcriptomic analysis has revealed significant heterogeneity among lung myofibroblasts, which arise from various cell types and are adapted to the altered microenvironment during pathological lung repair. This review provides an overview of recent research on the origins of lung myofibroblasts and the molecular pathways driving their formation, with a focus on the interactions between lung fibroblasts and epithelial cells, endothelial cells, and macrophages in the context of lung fibrosis. Based on these molecular insights, targeting the lung FMT could offer promising avenues for the treatment of IPF.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology & Toxicology, Medical College of Georgia at Augusta University, Augusta, GA 30912, USA.
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA 30912, USA.
- Vascular Biology Center, Medical College of Georgia at Augusta University, Augusta, GA 30912, USA.
- Research Service, Charlie Norwood Veterans Affairs Medical Center, Augusta, GA 30912, USA.
Förderung
- BLRD VA
- NHLBI NIH HHS
Zitieren
APA
Zhao, T., & Su, Y. (2025). Mechanisms and Therapeutic Potential of Myofibroblast Transformation in Pulmonary Fibrosis. Journal of Respiratory Biology and Translational Medicine, 2(1), 10001-10001. https://doi.org/10.70322/jrbtm.2025.10001
Vancouver
Zhao T, Su Y. Mechanisms and Therapeutic Potential of Myofibroblast Transformation in Pulmonary Fibrosis. Journal of Respiratory Biology and Translational Medicine. 2025;2(1):10001-10001. doi:10.70322/jrbtm.2025.10001
BibTeX
@article{Zhao2025,
author = {Zhao, Tianming and Su, Yunchao},
title = {Mechanisms and Therapeutic Potential of Myofibroblast Transformation in Pulmonary Fibrosis},
journal = {Journal of Respiratory Biology and Translational Medicine},
year = {2025},
volume = {2},
number = {1},
pages = {10001--10001},
doi = {10.70322/jrbtm.2025.10001}
}
EUVIMED